We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+25.81%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$241M
AUM Growth
+$50.3M
(+26%)
Cap. Flow
+$11.8M
Cap. Flow
% of AUM
4.88%
Top 10 Holdings %
Top 10 Hldgs %
9.37%
Holding
372
New
47
Increased
146
Reduced
160
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Brookfield Renewable
BEPC
|
+$1.51M |
| 2 |
Western Midstream Partners
WES
|
+$926K |
| 3 |
PSXP
PHILLIPS 66 PARTNERS LP
PSXP
|
+$707K |
| 4 |
Delek US
DK
|
+$681K |
| 5 |
CVR Energy
CVI
|
+$669K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMMU
Immunomedics Inc
IMMU
|
+$1.61M |
| 2 |
AIMT
Aimmune Therapeutics
AIMT
|
+$1.13M |
| 3 |
AIV
Aimco
AIV
|
+$1.1M |
| 4 |
Telefônica Brasil
VIV
|
+$1.01M |
| 5 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
+$988K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 29.53% |
| 2 | Real Estate | 18.96% |
| 3 | Energy | 16.61% |
| 4 | Materials | 11.31% |
| 5 | Utilities | 7.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KZR
251
DELISTED
Kezar Life Sciences
KZR
| $278K | 0.12% |
5,335
-1,034
| -16% | -$57.5K |
|
252
Prothena Corp
PRTA
$448M
| $278K | 0.12% |
23,175
-8,700
| -27% | -$103K |
|
253
Q32 Bio
QTTB
$435M
| $278K | 0.12% |
1,369
+216
| +19% | +$41.8K |
|
254
Ardelyx
ARDX
$1.24B
| $277K | 0.12% |
42,880
-3,895
| -8% | -$23.1K |
|
255
Compugen
CGEN
$212M
| $277K | 0.12% |
22,834
+685
| +3% | +$9.45K |
|
256
Legend Biotech
LEGN
$3.65B
| $277K | 0.12% |
+9,834
| New | +$283K |
|
257
Oaktree Specialty Lending
OCSL
$1.05B
| $277K | 0.12% |
16,555
-3,169
| -16% | -$49.2K |
|
258
Verastem
VSTM
$528M
| $277K | 0.12% |
10,830
-3,763
| -26% | -$75.6K |
|
|
OYST
259
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
| $277K | 0.12% |
14,729
+4,017
| +38% | +$86.6K |
|
260
ADC Therapeutics
ADCT
$140M
| $276K | 0.11% |
+8,616
| New | +$282K |
|
261
Black Diamond Therapeutics
BDTX
$95.1M
| $276K | 0.11% |
8,603
-317
| -4% | -$10.4K |
|
|
MRTX
262
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $276K | 0.11% |
1,256
-1,764
| -58% | -$381K |
|
|
KDMN
263
DELISTED
Kadmon Holdings, Inc.
KDMN
| $276K | 0.11% |
66,594
-861
| -1% | -$3.4K |
|
|
SYRS
264
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $275K | 0.11% |
2,532
-952
| -27% | -$86.9K |
|
|
MRNS
265
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $275K | 0.11% |
22,503
-9,734
| -30% | -$136K |
|
|
ETNB
266
DELISTED
89bio
ETNB
| $272K | 0.11% |
+11,154
| New | +$285K |
|
267
Iovance Biotherapeutics
IOVA
$2.04B
| $272K | 0.11% |
5,870
-4,580
| -44% | -$182K |
|
268
Madrigal Pharmaceuticals
MDGL
$12.6B
| $272K | 0.11% |
2,444
-435
| -15% | -$53.2K |
|
269
Quince Therapeutics
QNCX
$21.5M
| $272K | 0.11% |
49
+15
| +44% | +$133K |
|
|
GMDA
270
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
| $272K | 0.11% |
+32,455
| New | +$220K |
|
271
Cue Biopharma
CUE
$118M
| $271K | 0.11% |
722
+320
| +80% | +$128K |
|
272
Zymeworks
ZYME
$1.62B
| $271K | 0.11% |
5,726
-3,295
| -37% | -$153K |
|
|
GTHX
273
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $271K | 0.11% |
15,055
-1,658
| -10% | -$24.8K |
|
274
Geron
GERN
$898M
| $270K | 0.11% |
169,547
-20,716
| -11% | -$37.7K |
|
275
Gossamer Bio
GOSS
$101M
| $270K | 0.11% |
27,963
+2,834
| +11% | +$27.9K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
RC
Virtus ETF Advisers's Q4 2020 Portfolio in Review
As of Q4 2020, Virtus ETF Advisers held 372 positions worth $241M, up 26% from $191M the previous quarter. Its ten largest holdings account for 9.4% of the portfolio.
Virtus ETF Advisers deployed $11.8M of net new capital in Q4 2020, opening 47 new positions and adding to 146 existing holdings. Its largest new stake was Harmony Biosciences: 14,899 shares worth $539K.
By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 32% a quarter earlier, followed by Real Estate and Energy.
On the sell side, the largest reduction was Amicus Therapeutics, an estimated $572K trimmed.
- Virtus ETF Advisers's largest Q4 2020 buy was Harmony Biosciences: 14,899 shares worth $539K.
- Virtus ETF Advisers added most to Brookfield Renewable in Q4 2020, an estimated $1.51M increase.
- Virtus ETF Advisers's biggest Q4 2020 reduction was Amicus Therapeutics, cutting an estimated $572K.
- Virtus ETF Advisers fully exited Immunomedics Inc in Q4 2020, selling an estimated $1.61M.
- Virtus ETF Advisers's ten largest holdings make up 9.4% of its $241M portfolio in Q4 2020.
- Virtus ETF Advisers opened 47 new positions and closed 17 in Q4 2020.
- Virtus ETF Advisers's portfolio value rose 26% quarter-over-quarter to $241M.
Based on Virtus ETF Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.